Midday Report: Galmed (GLMD) Gains on May 13

Equities Staff  |

Galmed Pharmaceuticals Ltd (NASDAQ: GLMD) has risen $0.0251 (4.18%) and sits at $0.63, as of 11:13:21 est on May 13.

31,085 shares have exchanged hands.

The Company fell 29.41% over the last 5 days and shares lost 61.04% over the last 30 days.

Galmed is set to release earnings on 2022-05-30.

For technical charts, analysis, and more on Galmed visit the company profile.

About Galmed Pharmaceuticals Ltd

Galmed Pharmaceuticals Ltd. is a clinical stage drug development biopharmaceutical company for liver, metabolic and inflammatory diseases. Its lead compound, Aramchol™, a backbone drug candidate for the treatment of NASH and fibrosis is currently in a Phase 3 registrational study.It is also collaborating with the Hebrew University in the development of Amilo-5MER, a 5 amino acid synthetic peptide and plan to initiate a first in human study by the first quarter of 2021.

To get more information on Galmed Pharmaceuticals Ltd and to follow the company's latest updates, you can visit the company's profile page here: Galmed Pharmaceuticals Ltd's Profile. For more news on the financial markets be sure to visit Equities News. Also, don't forget to sign-up for the Daily Fix to receive the best stories to your inbox 5 days a week.

Sources: Symbol info widget is provided by TradingView based on 15-minute-delayed prices. All other article data is provided by IEX Cloud on 15-minute delayed prices or EOD company info.

Stock price data is provided by IEX Cloud on a 15-minute delayed basis. Chart price data is provided by TradingView on a 15-minute delayed basis.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer

Trending Articles

Will New AT&T, Dish Co-opetition Deal Work: Jeff Kagan
Cisco Down 12% in Premarket Trading Thursday After Top Line Miss and Lower Forecast
Under Armour CEO Patrik Frisk To Step Down in Surprise Announcement
Target Hits 52-Week Low After Missing Badly on First Quarter Earnings
DLocal Posts Record Q1, Fifth Consecutive 100%+ Revenue Growth Quarter
Another Crypto Winter Wipes Out Billions in Market Value
Inflation + Recession = Recipe for Volatility

Market Movers

Sponsored Financial Content